Novo Nordisk’s Concizumab Could Be First In New Class For Hemophilia

TFPI Inhibitors Have 20 Years Of Bad History

 
• By Alaric DeArment
  
Novo Nordisk presented data from its Phase III explorer7 trial of concizumab • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D